Literature DB >> 2739399

Experimental and clinical significance of endotoxin-dependent HLA-DR expression on monocytes.

S H Appel1, S R Wellhausen, R Montgomery, R C DeWeese, H C Polk.   

Abstract

For much of the last decade, an increasing number of surgeons have been interested in objective assessment of cellular contributors to host defense function. In order to study many of these processes, it is apparently desirable that the cells be isolated to the extent feasible for the purpose of analyzing a more or less pure population of cellular elements. The purpose of this paper is to describe the physiologic activation of mononuclear cells that occurs as a result of the isolation process. Therefore, it follows logically that such cells are therein intrinsically less responsive to further physiologic manipulation in vitro. Analyses of such data without an awareness of this intrinsic aberration will undoubtedly lead to misinterpretation of the capacity of such cells for further modulation by immunostimulants or by the intrinsic processes related to injury, anesthesia, and operation. Furthermore, it may indicate that certain agents, e.g., cytokines, are unable to stimulate cellular function when, in fact, the defense function of the cell has been initially stimulated by the isolation procedure. Fractionation of human peripheral blood over Hypaque-Ficoll and subsequent purification of monocytes by adherence to plastic lead to an increase in the relative density of HLA-DR on monocytes. This increase occurred when carried out in endotoxin lipopolysaccharide (LPS)-contaminated or LPS-depleted reagents. LPS, added experimentally to whole blood, enhanced HLA-DR expression on monocytes without further manipulation. Monocyte HLA-DR expression measured in whole blood was reduced in patients with major sepsis (n = 19) compared to normal subjects (n = 10).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2739399     DOI: 10.1016/0022-4804(89)90045-0

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

3.  [Immune paralysis in acute pancreatitis--HLA-DR antigen expression on CD14+DR+ monocytes].

Authors:  A Richter; T Nebe; R Kattermann; M Trede
Journal:  Langenbecks Arch Chir       Date:  1996

4.  Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease.

Authors:  K R Gardiner; A D Crockard; M I Halliday; B J Rowlands
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

5.  Changes in phenotypic patterns of blood monocytes after kidney transplantation and during acute rejection.

Authors:  V Švachová; L Krupičková; M Novotný; M Fialová; K Mezerová; E Čečrdlová; V Lánská; A Slavčev; O Viklický; O Viklický; I Stříž
Journal:  Physiol Res       Date:  2021-09-10       Impact factor: 1.881

6.  Non-classical MHC I-E negatively regulates macrophage activation and Th17 cell development in NOD mice.

Authors:  Chunhui Yang; Nining Guo; Jinhua Liu; Juhao Yang; Kai Zhu; Hui Xiao; Qibin Leng
Journal:  Sci Rep       Date:  2015-08-07       Impact factor: 4.379

7.  Laparoscopic Nissen fundoplication: The effects of high-concentration supplemental perioperative oxygen on the inflammatory and immune response: A randomised controlled trial.

Authors:  Mario Schietroma; Sara Colozzi; Beatrice Pessia; Francesco Carlei; Marino Di Furia; Gianfranco Amicucci
Journal:  J Minim Access Surg       Date:  2018 Jul-Sep       Impact factor: 1.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.